4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: 
-	Dare to Cure
-	Break Boundaries 
-	Beyond Yourself 
-	Prepare & Executive Relentlessly 

Join us in creating the future of genetic medicine.

Pappas Capital

Perceptive Advisors

Pfizer Venture Investments

QUAD Investment Management

Viking Global Investors

Longevity Vision Fund

MiraeAsset Financial Group

Berkeley Catalyst Fund (BCF)

Biotechnology Value Fund

BVF Partners

Chiesi Ventures

4D Molecular Therapeutics

4DMT is excited to be featured on BioSpace’s 2024 #BestPlacesToWork small employer list — a list of the top ranked life science employers in North America based on industry vote. Thank you, BioSpace for this honorable recognition, and our 4DMT family for making this award possible. Interested in joining our team? Learn more here: https://lnkd.in/ge8w9xnt

Thank you, Emily's Entourage! We are immensely honored to be a Dream Team Sponsor for the 2023 Scientific Symposium taking place next month. It's a privilege to stand alongside organizations like EE and work together to accelerate treatments for the final 10% of individuals with #cysticfibrosis. We are grateful for the passionate support from EE and the entire cystic fibrosis community.

We are gratified to receive additional financial and research support from the CF Foundation for our cutting edge, next-generation lung gene delivery technology!

This month, our #4DMT team will be participating in a fireside chat at the 6th Annual Evercore ISI #HealthCONx Conference. We look forward to connecting! Register for the webcast here: https://lnkd.in/e-uZM_6S
#investorconference

Last week, the 4DMT team participated at #NACFC 2023, where we shared positive data from our Phase 1/2 AEROW clinical trial of 4D-710. We are grateful for the opportunity to connect with the cystic fibrosis community and help advance new treatments for CF.

Today, we announced our third quarter financial results and operational highlights, including updates across our ophthalmology, pulmonology, and cardiology programs. Read more about our recent progress and anticipated upcoming milestones: https://lnkd.in/gpUQkv5w  #earnings

Our team was thrilled to be on-site in San Francisco this past weekend for #AAO23 to hear from colleagues and exhibitors on the latest technologies and treatments in ophthalmology.

We are thrilled to present positive interim data from Phase 1/2 AEROW clinical trial of aerosolized 4D-710 at Cystic Fibrosis Foundation’s North American Cystic Fibrosis Conference this week in Phoenix, Arizona. 
 
We also would like to warmly welcome Alan H. Cohen, MD, who has joined 4DMT as SVP, Therapeutic Area Head of Pulmonology. 
 
Finally, we are gratified to announce that the Cystic Fibrosis Foundation has increased their funding commitment under our research agreement by $2.8 million to a total of $6.3 million. The increased financial commitment brings their total historical commitment to the 4DMT CF program to over $20 million.
 
Stop by kiosk #2 to connect with our team and learn more about the latest progress with 4D-710, an investigational genetic medicine for adults with #cysticfibrosis lung disease. Read the full release here: https://lnkd.in/dgKfuVwd 
 
Register for the webcast here: https://lnkd.in/g6ztcSZR

People with #CysticFibrosis who are not amenable or do not respond to CFTR modulators deserve treatments that address the underlying cause of the disease. We are on a mission to develop a potentially transformative new therapy to treat a broad range of people with #CF. Learn about 4D-710: https://lnkd.in/gzw65bYm

Today, we announced alignment with the FDA on a plan to lift the clinical hold on our Phase 1/2 INGLAXA clinical trial for 4D-310 for Fabry disease #cardiomyopathy. In addition, we expect to share additional interim clinical data from INGLAXA for all 6 patients treated to date in Q1 2024. Read the full press release here: https://lnkd.in/gPdKNQpm 
#fabrydisease

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	5.79M -	14.13M 144.04%	6.99M 50.56%	13.61M 94.85%	18.04M 32.52%	3.13M 82.65%	20.72M 562.29%
cost of revenue			38.72M -	53.04M 36.99%	3.02M 94.31%	3.88M 28.48%	5.75M 48.17%
gross profit	5.79M -	14.13M 144.04%	-31.73M 324.57%	-39.43M 24.25%	15.02M 138.09%	-751K 105.00%	14.97M 2,093.87%
selling and marketing expenses							-5.75M -
general and administrative expenses	3.49M -	6.17M 76.76%	13.89M 125.31%	17.24M 24.06%	28.01M 62.50%	32.91M 17.48%	36.49M 10.90%
selling general and administrative expenses	3.49M -	6.17M 76.76%	13.89M 125.31%	17.24M 24.06%	28.01M 62.50%	32.91M 17.48%	30.75M 6.57%
research and development expenses	13.57M -	18.36M 35.28%	38.72M 110.86%	53.04M 36.99%	61.36M 15.69%	80.25M 30.79%	97.10M 20.99%
other expenses	-40K -	-2K 95%	-46K 2,200%	-181K 293.48%	16K 108.84%	2.54M 15,762.50%	-181K 107.13%
cost and expenses	17.06M -	24.53M 43.76%	52.61M 114.49%	70.28M 33.57%	89.37M 27.17%	113.16M 26.62%	133.59M 18.05%
operating expenses	17.06M -	24.53M 43.76%	52.61M 114.49%	70.28M 33.57%	89.37M 27.17%	113.16M 26.62%	127.84M 12.97%
interest expense						-6.42M -
ebitda	-10.65M -	-9.70M 8.87%	-39.49M 306.99%	-55.22M 39.85%	-71.33M 29.18%	-110.03M 54.25%	-107.12M 2.65%
operating income	-11.27M -	-10.40M 7.74%	-50.76M 388.16%	-56.66M 11.62%	-71.33M 25.89%	-110.03M 54.25%	-112.87M 2.58%
depreciation and amortization	626K -	697K 11.34%	11.28M 1,518.08%	1.44M 87.21%	3.02M 109.29%	3.88M 28.48%	5.75M 48.17%
total other income expenses net	-40K -	-2K 95%	1.46M 73,000%	-29K 101.99%	16K 155.17%	2.54M 15,762.50%	12.03M 374.00%
income before tax	-11.22M -	-9.55M 14.90%	-49.31M 416.24%	-56.69M 14.98%	-71.32M 25.80%	-107.49M 50.73%	-100.84M 6.19%
income tax expense	-89K -	848K 1,052.81%	3.63M 328.42%	-152K 104.18%	-3.02M 1,886.84%	-6.42M 112.52%
net income	-11.22M -	-9.55M 14.90%	-52.94M 454.28%	-56.54M 6.80%	-68.30M 20.79%	-101.08M 47.99%	-100.84M 0.24%
weighted average shs out	14.84M -	12.52M 15.62%	26.49M 111.64%	26.68M 0.71%	27.73M 3.93%	32.35M 16.66%	39.13M 20.95%
weighted average shs out dil	14.84M -	12.52M 15.62%	26.49M 111.64%	26.68M 0.71%	27.73M 3.93%	32.35M 16.66%	39.13M 20.95%
eps	-0.76 -	-0.76 0%	-2 163.16%	-2.12 6.00%	-2.46 16.04%	-3.12 26.83%	-2.58 17.31%
epsdiluted	-0.76 -	-0.76 0%	-2 163.16%	-2.12 6.00%	-2.46 16.04%	-3.12 26.83%	-2.58 17.31%

NASDAQ:FDMT

4D Molecular Therapeutics Inc

Last Close

18.52

26/07 20:00

Market Cap

1.20B

Beta: 2.49

Volume Today

680.15K

Avg: 518.41K

PE Ratio

−14.82

PFCF: −18.46

Preview